Turing Pharmaceuticals AG is a privately-held biopharmaceutical company with offices in New York City and Zug, Switzerland. Turing focuses on developing and commercializing innovative treatments for serious diseases and conditions across a broad range of therapeutic areas, for which there are currently limited or no treatment options. Products being developed include intranasal ketamine for a variety of disorders and Syntocinon® (oxytocin nasal solution) for multiple indications. Vecamyl® (mecamylamine HCl tablets) is Turing's first commercial product. On August 10, 2015, the company announced the acquisition of Daraprim® from Impax Laboratories, Inc.